Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy

Endocrine Research

Volumn 40, Issue 1, 2015, Pages 25-28

  Kruljac, Ivan ^a   Solter, Darko ^b   Vrkljan, Ana Marija ^a   Solter, Miljenko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Euthyroidism; Graves disease; Methimazole; Remission

Indexed keywords

LIOTHYRONINE; PROPYLTHIOURACIL; THIAMAZOLE; THYROID HORMONE; ANTITHYROID AGENT; THYROXINE;

ADULT; AGE DISTRIBUTION; ARTICLE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUTHYROIDISM; FEMALE; GOITER; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RASH; REMISSION; SEX DIFFERENCE; THYROID HORMONE BLOOD LEVEL; TREATMENT DURATION; ADOLESCENT; AGED; BLOOD; DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITHYROID AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAVES DISEASE; HUMANS; MALE; METHIMAZOLE; MIDDLE AGED; REMISSION INDUCTION; THYROXINE; TREATMENT OUTCOME; TRIIODOTHYRONINE; YOUNG ADULT;

EID: 84921297878     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2014.914038     Document Type: Article

References (10)

1. Laurberg P. Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 2006;155:783-6.
2. Benker G, Vitti P, Kahaly G, et al. Response to methimazole in Graves' disease. The European Multicenter Study Group. Clin Endocrinol (Oxf) 1995;43:257-63.
3. Romaldini JH, Bromberg N, Werner RS, et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983;57:563-70.
4. Benker G, Reinwein D, Kahaly G, et al. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf) 1998;49:451-7.
5. Abraham P, Avenell A, McGeoch SC, et al. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 2010;20:CD003420.
6. Paschke R, Vogg M, Kristoferitsch R, et al. Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease. J Clin Endocrinol Metab 1995;80:2470-4.
7. Bahn RS, Burch HB, Cooper DS, et al. American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011;17: 456-520.
8. Allahabadia A1, Daykin J, Holder RL, et al. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000;85:1038-42.
9. Holm IA1, Manson JE, Michels KB, et al. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med 2005;165:1606-11.
10. Volpe R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyteimmunocyte signalling. Curr Pharm Des 2001;7:451-60.